rs1051296 — SLC19A1 SLC19A1 variant (RFC1)

3'UTR variant in the reduced folate carrier that affects miR-595 binding, altering cellular folate and methotrexate uptake efficiency

See your personal result for SLC19A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC19A1 rs1051296 — The Folate Carrier's Silent Regulator

SLC19A1 — also known as RFC1 (reduced folate carrier 1) — is the primary gateway through which folate enters your cells. Without efficient RFC1 function, even a diet rich in folate or supplementation with folic acid may not fully replenish cellular folate stores, because the transporter is the rate-limiting step between circulating folate and the intracellular methylation machinery. The rs1051296 variant sits in the 3' untranslated region 11 The 3'UTR is the sequence after the stop codon in messenger RNA; it controls mRNA stability and is a binding site for regulatory microRNAs of SLC19A1 and influences how strongly a microRNA called miR-595 can suppress RFC1 production.

The Mechanism

The rs1051296 variant creates or disrupts a binding site for miR-59522 miR-595
A regulatory microRNA that binds to the 3'UTR of target mRNAs and reduces their translation into protein. The A allele (reported on the plus strand; equivalent to T on the coding strand used in most papers) is the sequence that miR-595 recognizes. When miR-595 binds, it reduces SLC19A1 messenger RNA translation, lowering the amount of RFC1 transporter protein at the cell surface. The C allele (equivalent to G on the coding strand) disrupts this binding site — miR-595 cannot bind as effectively, so RFC1 levels remain higher. The net result is that AA homozygotes have meaningfully lower RFC1 expression than CC homozygotes, with AC heterozygotes in between.

The Evidence

The functional mechanism was established in a 2014 pharmacogenomic study of 131 Chinese children with acute lymphoblastic leukemia33 2014 pharmacogenomic study of 131 Chinese children with acute lymphoblastic leukemia
Wang SM et al. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with ALL. Med Oncol. 2014. Methotrexate is a folate antagonist transported into cells almost exclusively by RFC1, making it an ideal pharmacological probe for transporter function. Children with the AA genotype (plus strand) had average 24-hour methotrexate plasma levels of 29.97 µmol/L, compared to 39.01 µmol/L for CC homozygotes. More strikingly, only 8.6% of AA carriers achieved the therapeutic threshold of >40 µmol/L, versus 40.0% of CC carriers (p=0.02). This disparity reflects reduced cellular uptake rather than a kinetic elimination difference — AA carriers retain more methotrexate in plasma because less enters cells.

The 2018 mechanistic study44 2018 mechanistic study
Wang SM et al. MiR-595 suppresses the cellular uptake and cytotoxic effects of methotrexate by targeting SLC19A1. Basic Clin Pharmacol Toxicol. 2018 confirmed the molecular basis using luciferase reporter assays. Introducing miR-595 mimics into leukemia cell lines caused a significant drop in SLC19A1 reporter activity only when the A-allele 3'UTR was present (p<0.01), demonstrating direct miR-595 binding at this site. miR-595 overexpression also reduced RFC1 protein levels, intracellular methotrexate accumulation, and drug-induced cytotoxicity.

Beyond pharmacogenomics, a 2025 case-control study55 2025 case-control study
Nasir I et al. SLC19A1 Gene Polymorphism; Risk Factor for Preeclampsia. J Coll Physicians Surg Pak. 2025 in 332 Pakistani women found that the CA and AA genotypes were associated with significantly elevated preeclampsia risk (p<0.03 and p<0.001 respectively), while the CC genotype appeared protective. Folate adequacy compounded the genotype effect: women with the CA genotype and low circulating folate had the highest preeclampsia susceptibility. This finding is biologically plausible given the critical role of one-carbon metabolism in placental function and maternal vascular health.

Practical Actions

The most direct implication of reduced RFC1 transport efficiency is that dietary and supplemental folate may require higher intake or more bioavailable forms to achieve the same intracellular concentration as in CC carriers. Since methotrexate uses the same transporter, AA carriers receiving methotrexate therapy may need dose adjustments to achieve therapeutic drug levels — this should be discussed with the prescribing physician. For those planning or carrying a pregnancy, ensuring adequate active folate intake is especially important given the preeclampsia association.

Interactions

rs1051296 interacts biologically with rs1051266 (SLC19A1 G80A, the missense variant at codon 27 of RFC1). rs1051266 affects the transporter's affinity for folate substrates, while rs1051296 affects the amount of transporter expressed. Carrying reduced-function alleles at both sites compounds the transport deficit. Both variants also interact with MTHFR variants (rs1801133 C677T, rs1801131 A1298C): impaired folate delivery (SLC19A1) combined with impaired folate utilization (MTHFR) creates a compounding one-carbon cycle burden, with potential for elevated homocysteine and reduced methylation capacity even at dietary folate intakes considered adequate for most people.

Drug Interactions

methotrexate reduced_efficacy literature

Nutrient Interactions

folate reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

CC Efficient Transport Beneficial

Two copies of the high-efficiency allele — optimal RFC1-mediated folate uptake

You carry two C alleles at rs1051296, the genotype associated with the highest RFC1 (reduced folate carrier) expression. The C allele disrupts the miR-595 binding site in the SLC19A1 3' untranslated region, meaning miR-595 cannot suppress RFC1 production as effectively. As a result, CC carriers express more folate carrier protein at the cell surface and have more efficient cellular folate uptake than AA or AC carriers. About 19% of people carry this genotype. In pharmacogenomic studies, CC carriers achieve the highest intracellular methotrexate concentrations and are most likely to reach therapeutic drug thresholds.

AC Intermediate Transport Intermediate

One copy of the reduced-transport allele — moderately efficient folate uptake

The 2014 pharmacogenomic study (PMID 24927955) found that GT heterozygotes on the coding strand (= AC on the plus strand) had average 24-hour methotrexate levels of 32.34 µmol/L — between the AA value of 29.97 and the CC value of 39.01 µmol/L, consistent with a codominant effect on RFC1 expression. About 26.8% of AC carriers achieved the >40 µmol/L therapeutic threshold, compared to 8.6% for AA and 40.0% for CC. The practical implication is a mild-to-moderate reduction in RFC1-mediated folate transport, partially compensated by adequate dietary folate intake.

AA Reduced Transport Reduced

Two copies of the reduced-transport allele — lower cellular folate and methotrexate uptake

In the 2014 pediatric ALL study (PMID 24927955), AA homozygotes (TT on the coding strand) had the lowest average 24-hour methotrexate plasma concentration (29.97 µmol/L vs 39.01 µmol/L for CC), and only 8.6% reached the >40 µmol/L therapeutic threshold compared to 40.0% of CC carriers (p=0.02). The 2018 mechanistic study (PMID 29345051) confirmed that miR-595 binding to the A-allele 3'UTR reduces RFC1 protein levels, intracellular methotrexate accumulation, and drug cytotoxicity in cell lines. For dietary folate, the consequence is that cellular import may be less efficient, meaning standard recommended intakes may provide a lower intracellular folate concentration than in CC carriers — particularly under conditions of high demand (pregnancy, chronic stress, high-folate-demand tissues). A 2025 case-control study (PMID 40055164) found significantly elevated preeclampsia risk in AA carriers (p<0.001), with the combination of low folate intake and reduced RFC1 transport as the likely mechanism.